IR

Analytical Standards Market Worth $2.1 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, October 17, 2023
Environmental protection, Food, Data integrity, Food safety, Consumer confidence, SPEX, Drug development, Ultraviolet–visible spectroscopy, Waters Corporation, LGC, Organization, Quality control, Calibration, Food security, Safety, Biotechnology, Laboratory, Trust, GPC, Growth, IR, Research, Sparganothina inbiana, Merck Group, Policy, Drink, CRMS, Agilent Technologies, PerkinElmer, Environmental monitoring, Research and development, Fine chemical, 3D printing, Surveying, Medical device, Mallinckrodt

The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.

Key Points: 
  • The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.
  • Based on application, the pharmaceutical & life sciences standards segment is estimated to hold the largest market share of the analytical standards market during the forecast period.
  • In 2023, Asia Pacific is expected to register the highest CAGR in the market for analytical standards during the forecast period.
  • Data Integrity: Analytical standards contribute to maintaining the integrity of scientific data, which is fundamental in decision-making processes, research, and policy development.

Analytical Standards Market Worth $2.1 Billion | MarketsandMarkets

Retrieved on: 
Tuesday, October 17, 2023
Environmental protection, Food, Data integrity, Food safety, Consumer confidence, SPEX, Drug development, Ultraviolet–visible spectroscopy, Waters Corporation, LGC, Organization, Quality control, Calibration, Food security, Safety, Biotechnology, Laboratory, Trust, GPC, Growth, IR, Research, Sparganothina inbiana, Merck Group, Policy, Drink, CRMS, Agilent Technologies, PerkinElmer, Environmental monitoring, Research and development, Fine chemical, 3D printing, Surveying, Medical device, Mallinckrodt

The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.

Key Points: 
  • The pharmaceutical & life sciences standards segment accounted for the largest share of analytical standards in 2023-2028.
  • Based on application, the pharmaceutical & life sciences standards segment is estimated to hold the largest market share of the analytical standards market during the forecast period.
  • In 2023, Asia Pacific is expected to register the highest CAGR in the market for analytical standards during the forecast period.
  • Data Integrity: Analytical standards contribute to maintaining the integrity of scientific data, which is fundamental in decision-making processes, research, and policy development.

Banco Santander Chile: Announces Third Quarter 2023 Analyst and Investor Webcast / Conference Call

Retrieved on: 
Friday, October 13, 2023
BSAC, Banco Santander Chile, NYSE, Bank, CFO, Management, IR, Banco Santander

SANTIAGO, Chile, Oct. 13, 2023 (GLOBE NEWSWIRE) -- You are cordially invited to participate in Banco Santander Chile's (NYSE: BSAC) conference call-webcast on Friday, November 3, 2023, at 10.00 AM (New York Time) where we will discuss 3Q 2023 financial results.

Key Points: 
  • SANTIAGO, Chile, Oct. 13, 2023 (GLOBE NEWSWIRE) -- You are cordially invited to participate in Banco Santander Chile's (NYSE: BSAC) conference call-webcast on Friday, November 3, 2023, at 10.00 AM (New York Time) where we will discuss 3Q 2023 financial results.
  • The Bank's Officers participating in the conference call are: Emiliano Muratore, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Carmen Gloria Silva, Economist.
  • The Management Commentary report will be published on October 31, 2023, before the market opens.
  • If you have any questions, please contact Cristian Vicuña at Banco Santander Chile at [email protected] , Rowena Lambert at [email protected] or Claudia Villalon at [email protected]

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

Retrieved on: 
Thursday, October 12, 2023
SL, Autoimmunity, Government, Headache, DSM-IV codes, CD40L, Research, Risk, Infection, COVID-19, Binge eating disorder, Smallpox, Central nervous system, Upsher-Smith Laboratories, Fibromyalgia, Hydrogen chloride, Annual report, Prader–Willi syndrome, PPAR, Pain, Obesity, Sumatriptan, Breakthrough therapy, Neurology, Cancer, FDA, Long, IR, Migraine, CNS, MDD, Security (finance), Disease, Therapy, Failure, ThinkEquity, Mandarin Oriental Hotel Group, Long COVID, Gustav Neuring, Social anxiety disorder, Orphan drug, Psychiatry, Conference, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.

Key Points: 
  • CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients

Retrieved on: 
Wednesday, October 11, 2023
Majesty of the Seas, Nasdaq First North, Faron Pharmaceuticals, Quality of life, Optimus, Capillary leak syndrome, Standard of care, ORR, AML, EST, Webcast, Acute myeloid leukemia, IR, Bone marrow, Hemophagocytic lymphohistiocytosis, AIM, HMA, Syndrome, Cryptogenic organizing pneumonia, SOC, MDS, Prognosis, Patient, Phase II, Pharmaceutical industry, Online shopping, Fårö

TURKU, Finland and BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage reprogramming for effective anticancer immunotherapies, today announces updated data from the Phase 1/2 BEXMAB study investigating bexmarilimab in combination with standard of care (SoC) in relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients having failed hypomethylating agents (HMAs).

Key Points: 
  • The most recent data includes read outs from a total of 22 patients (r/r AML with 12 patients, MDS frontline and MDS HMA-failed patients with five patients each) who have completed at least two or more treatment cycles.
  • Eight of 11 patients achieved complete remission in the bone marrow with or without blood count recovery.
  • The highest single indication-specific ORR was observed among HMA-failed MDS patients (4 out of 5 patients; 80%).
  • Faron plans to increase the number of US clinical sites from two to five sites to accelerate study recruitment.

Grimaldi Forum Monaco Elevates Security and Visitor Experience with State-of-the-Art AI Technology from i-PRO

Retrieved on: 
Tuesday, October 10, 2023
COVID-19, Grimaldi Forum, Anomaly, Scene, VMD, Exhibition, Congestion, MES, Light, Person, Forum, IR, Loitering munition, GFM, Casino, Mobile phone, Camera, Online shopping, Medical device, Fisheye, Safety

Located in the city-state of Monaco, the Grimaldi Forum serves as a prominent venue for conferences, conventions, cultural events, and world-class art exhibitions.

Key Points: 
  • Located in the city-state of Monaco, the Grimaldi Forum serves as a prominent venue for conferences, conventions, cultural events, and world-class art exhibitions.
  • Grimaldi Forum was able to considerably reduce the number of cameras required, thereby saving money.
  • The advanced AI analytics in these cameras enable Grimaldi Forum to detect congestion, manage visitor traffic flow, and count the number of people in specific areas.
  • For a detailed case study on the Grimaldi Forum Monaco’s use of i-PRO technology, please go to https://i-pro.com/products_and_solutions/en/surveillance/solutions/case-... .

Invitation Q3 2023 Trading Update Conference Call

Retrieved on: 
Tuesday, October 17, 2023
Q&A, CFO, IR, LINK, HERE

Mike Allison, CEO, and Fabian Chiozza, CFO will report on the business conditions during the third  quarter of the year and give you an update on our expectations for the rest of 2023.

Key Points: 
  • Mike Allison, CEO, and Fabian Chiozza, CFO will report on the business conditions during the third  quarter of the year and give you an update on our expectations for the rest of 2023.
  • After the formal remarks, there will be time for a moderated Q&A session.
  • Participants are asked to pre-register HERE and will receive dedicated dial-in details to easily and quickly access the call.
  • The conference call will be available in the IR section of our website ( LINK ) for replay purposes approximately one hour after the event.

MBH Corporation Plc: Issue of Equity

Retrieved on: 
Tuesday, October 17, 2023
MAR, Financial Conduct Authority, IR, Security (finance), Treasury

MBH Corporation Plc (AQSE:M8H), a diversified investment holding company, announces that it will be issuing 1,823,302 Ordinary Shares of €0.30 per share (“New Shares”), as follows:

Key Points: 
  • MBH Corporation Plc (AQSE:M8H), a diversified investment holding company, announces that it will be issuing 1,823,302 Ordinary Shares of €0.30 per share (“New Shares”), as follows:
    The New Shares rank pari passu with existing shares in issue.
  • Following this issue, the Company's issued share capital consists of 5,980,739 Ordinary Shares, each share carrying the right to one vote.
  • The Directors of the Company accept responsibility for the contents of this announcement.
  • For IR and media enquiries:
    Dissemination of a Regulatory Announcement that contains inside information in accordance with the Market Abuse Regulation (MAR), transmitted by EQS Group.

EQS-News: The NAGA Group AG: NAGA continues profitable growth path reaching 15% EBITDA for the first nine months of 2023 from its brokerage business  

Retrieved on: 
Tuesday, October 17, 2023
News, Acquisition, Committee on Capital Markets Regulation, NAGA Group, NAGA, EUR, Bank statement, EBITDA, Capital market, Growth, IR, Marketing, KPI-driven code analysis, Software, ISIN, XETRA, Security (finance), Rare-earth element, Lithium, Cryptocurrency

Furthermore, the Group reported preliminary year-to-date sales of EUR 28.4 million per September 30th 2023 from its brokerage business, delivering an EBITDA ratio of around 15%.

Key Points: 
  • Furthermore, the Group reported preliminary year-to-date sales of EUR 28.4 million per September 30th 2023 from its brokerage business, delivering an EBITDA ratio of around 15%.
  • One of the key factors contributing to this growth is the reduction in operational and marketing costs.
  • The NAGA Group has also expanded its presence in new and emerging markets, capitalizing on the increasing popularity of social investing and e-payments.
  • A notable achievement in the first nine months of 2023 is the highly successful optimization of NAGA's user acquisition strategy.

Pagaya Announces Timing of Third Quarter 2023 Earnings Release

Retrieved on: 
Monday, October 16, 2023
Payments, Professional Services, Other Technology, Technology, Fintech, IR, IDT, Communications satellite, Broadcasting, Cryptocurrency

Pagaya Technologies (NASDAQ: PGY) intends to announce its third quarter 2023 earnings on November 2, 2023.

Key Points: 
  • Pagaya Technologies (NASDAQ: PGY) intends to announce its third quarter 2023 earnings on November 2, 2023.
  • A conference call to discuss those earnings will be held on the same day at 8:30 a.m.
  • Details to register for the live webcast presentation and dial-in information will be available on Pagaya’s IR website located at investor.pagaya.com .
  • The webcast replay will be available on the IR website following the conclusion of the event.